1 There
were no acute or late grade 5 toxic effects.
2 There
were no adverse events either immediately or at 2-week follow
3 Acceptability of the intervention was high and there
were no adverse events.
4 There
were no associations between induction, graft loss, and incid
5 However, there
were no associations between protein clusters and any musculo
6 neovascular glaucoma was noted in 1 patient (2%), and there
were no cases of corneal opacity.
7 There
were no clinical signs of bowel ischaemia during the follow-u
8 However, there
were no correlations between ascorbic acid and other biomarke
9 There
were no correlations between drug concentrations and HIV DNA/
10 There
were no deaths in the ultralow-risk tamoxifen-treated arm at
11 In a modified intent-to-treat population, there
were no differences between latiglutenase and placebo groups
12 At the post-test (26 wk), there
were no differences between the iCST and TAU groups in the ou
13 There
were no differences in allergic disease between LEAP groups.
14 There
were no differences in any specificity measures.
15 There
were no differences in Model for End-Stage Liver Disease incl
16 ffected by development of intestinal inflammation and there
were no differences in previously published metabolic markers
17 regression and adjusting for socioeconomic variables, there
were no differences in QOL or functional scores in the benign
18 mbocytopenia were prolonged in the intensive arm, but there
were no differences in serious nonhematological toxicities.
19 There
were no differences in the change from baseline in vessel wal
20 During 2-year follow-up, there
were no differences of survival rates and occurrences of newl
21 way inflammation, mucus, fibrosis, and airway smooth muscle
were no different in Ormdl3(Delta2-3/Delta2-3)/CC10 and wild-
22 After a median follow-up of 32 months, there
were no grade 3 toxicities.
23 There
were no indications of acute toxicity up to 7 days after inst
24 There
were no indications of transgenerational acclimation to ocean
25 There
were no large imbalances between drug groups on baseline fact
26 s occurred for 2 consecutive years or when state death data
were no longer available (that is, from 2014 onward).
27 There
were no meaningful changes in body composition.On the basis o
28 cted to date suggested that these commonly studied variants
were no more associated with the disorder than would be expec
29 There
were no participants.
30 Safety was not explicitly addressed in any study, but there
were no reports of adverse events.
31 Conversely, there
were no safety concerns with very low LDL-cholesterol concent
32 There
were no serious adverse events or discontinuations due to adv
33 There
were no significant between-group differences in the secondar
34 There
were no significant differences among the NAFL, NASH, and obe
35 There
were no significant differences among the treatment groups wi
36 olonoscopy follow-up within 8 to 30 days (n = 27176), there
were no significant differences between follow-up at 2 months
37 There
were no significant differences between groups in patients' g
38 Results There
were no significant differences between morning and afternoon
39 There
were no significant differences between the 2 experimental gr
40 ASD patients and family members compared to controls, there
were no significant differences in allele frequencies between
41 There
were no significant differences in baseline demographics or t
42 There
were no significant differences in CSF cytokine or chemokine
43 There
were no significant differences in image contrast, sensitivit
44 edicare beneficiaries treated by a general internist, there
were no significant differences in overall 30-day mortality r
45 There
were no significant differences in recurrent myocardial infar
46 There
were no significant differences in the odds ratios for treatm
47 There
were no significant differences in transplant and pretranspla
48 There
were no significant interactions of genotypes with calcium su
49 There
were no statistically significant associations between low IO
50 ients presenting to the ED with acute extremity pain, there
were no statistically significant or clinically important dif